Clinical trials: Relapsed/Refractory B-Cell Neoplasms
Lymphoma, Non-Hodgkin
A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)
This study is designed to evaluate the safety, tolerability, pharmacokinetic profile, and antitumor efficacy of DZD8586 in participants with relapsed or refractory B-NHL.
- Trial name
- NCT05844956
- Testing
- DZD8586
- Where
- 6 sites in China
- Volunteers
- 17 people
- Sponsor
- Dizal Pharmaceuticals
Solid Tumor, Lymphoma
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
The potency of immune checkpoint blockade is limited in most solid malignancies, one possible reason for which is tumor microenvironment.
- Trial name
- NCT04407741
- Testing
- SHR2554+SHR1701, SHR1701
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Relapsed or Refractory B-cell Lymphoma
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
To evaluate the efficacy and safety of selinexor combined with R-GDP regimen in the treatment of patients with TP53-altered relapsed or refractory B-cell lymphoma.
- Trial name
- NCT06062641
- Testing
- SR-GDP
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Non-Hodgkin's Lymphoma
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
The purpose of this study is to test the safety of delivering the patients' own immune cells, called T cells, after the high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT).
- Trial name
- NCT01840566
- Testing
- Carmustine, Etoposide, Cytarabine
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B Cell Lymphoma
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial is studying how well Akt inhibitor MK2206 works in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT01481129
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 9 sites in France
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00005631
- Testing
- filgrastim, rituximab, carboplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
B Cell, Acute Lymphoblastic Leukemia
Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias
Background Acute lymphoblastic leukemia (ALL) accounts for about 25 percent of childhood cancers and for about 20 percent of adult leukemias.
- Conditions
- B Cell, Acute Lymphoblastic Leukemia, Relapsed/Refractory
- Trial name
- NCT05969002
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
A first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of ZE50-0134 administered orally in healthy volunteers.
- Trial name
- NCT06787131
- Testing
- Rabeprazole 20 mg, Itraconazole (200 mg)
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Lomond Therapeutics Holdings, Inc.
Leukemia
4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies
The goal of this clinical research study is to find the highest tolerable dose of 4'-thio-araC (thiarabine) that can be given to patients with advanced blood cancer.
- Trial name
- NCT01139151
- Testing
- 3 Day Thiarabine, 5 Day Thiarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study will evaluate the pharmacokinetics, safety, tolerability, and efficacy of glofitamab as a single agent following a fixed single dose of obinutuzumab in Chinese patients with relapsed or refractory (R/R) diffuse large…
- Trial name
- NCT04657302
- Testing
- Obinutuzumab, Glofitamab, Tocilizumab
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Relapsed/Refractory B-Cell Malignancies
CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies
This study seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B cell surface antigen CD19…
- Trial name
- NCT04943016
- Testing
- CD19 Chimeric Antigen Receptor (CAR) T Cells
- Volunteers
- 12 people
- Sponsor
- National Taiwan University Hospital
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
This phase II trial is studying how well giving rituximab and cyclophosphamide together with bortezomib and dexamethasone (R-CyBor-D) works in treating patients with relapsed or refractory low-grade follicular lymphoma…
- Conditions
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT00711828
- Testing
- Bortezomib, Rituximab, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
B-cell Non Hodgkin Lymphoma
N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
The purpose of this clinical trial is to learn whether the study drug N-803 is safe and tolerable in patients with B-cell non-Hodgkin lymphoma who have undergone CAR T-cell therapy.
- Trial name
- CARMEN-803 (NCT07049432)
- Testing
- N803
- Where
- United States
- Sponsor
- University of Utah
B-cell Lymphoma
Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
To evaluate the safety and effecacy of Orelabrutinib therapy in patients with relapsed or refractory B-cell lymphoma (including R /rCLL/SLL and R /rMCL) who are intolerant to ibrutinib/zanubrutinib or other BTK inhibitors
- Trial name
- NCT05495828
- Testing
- Orelabrutinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Relapsed or Refractory B-cell Lymphomas
The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
The present study is an exploratory study. Patients who meeting the enrollment conditions for relapsed or refractory B-cell lymphoma receive a single intravenous dose of CD20-CART cells.
- Trial name
- NCT03576807
- Testing
- CD20 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xin Wang
Multiple Myeloma
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
- Trial name
- CAMMA 2 (NCT05535244)
- Testing
- Cevostamab, Tocilizumab
- Where
- 27 sites in United States, Australia and 6 more
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia, Relapse Leukemia
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
Observational study aimed at describing the characteristics and outcome of CLL patients who started treatment with venetoclax-based regimens according to the local label outside clinical trials in Italy in a period of time…
- Conditions
- Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia
- Trial name
- NCT04282811
- Testing
- Venetoclax
- Where
- 27 sites in Italy
- Volunteers
- 321 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Non-Hodgkin's B-cell Lymphoma
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR039 in treatment of relapsed or refractory NHL patients
- Trial name
- NCT04317885
- Testing
- Prizloncabtagene Autoleucel
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Tongji Hospital, Tongji University School of Medicine
Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT01534715
- Testing
- IMGN529
- Where
- 7 sites in United States, Switzerland
- Volunteers
- 49 people
- Sponsor
- ImmunoGen, Inc.
Chronic Lymphocytic Leukemia (CLL)
An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)
This is a phase 2, open-label, single institution trial of combination of intravenous (IV) ofatumumab and oral GSK2110183 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT01532700
- Testing
- Ofatumumab with GSK2110183
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.